China Wireless Comms (SVFC) 0.0001 $SVFC
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 5.70 (-0.66), CBMG: 13.74 (-0.31), OCAT: 8.47 (+0.01), ZBH: 128.30 (-1.61), PFE: 34.79 (-0.32), LLY: 79.84 (-0.42), GSK: 44.32 (-0.08), GLPG: 53.49 (-0.92), AXSM: 7.32 (+0.31), OMER: 11.31 (-0.20), CANF: 2.21 (-0.04), AST: 2.98 (-0.11), AKTX: 9.82 (+0.47)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.66 (+0.07), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13), MESO: 5.70 (-0.66), ATHX: 1.98 (-0.04), BXLT: 46.02 (-0.18)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.13 (-0.03), PSTI: 1.66 (+0.07), ATHX: 1.98 (-0.04), CLBS: 5.88 (-0.13)
Global Wounds Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/wwsp8b/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wounds Overview - Therapeutics Development - Pipeline Products for Wounds - Overview - Pipeline Products for Wounds - Comparative Analysis - Wounds - Therapeutics under Development by Companies - Wounds - Therapeutics under Investigation by Universities/Institutes - Wounds - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wounds - Products under Development by Companies - Wounds - Products under Investigation by Universities/Institutes - Wounds - Companies Involved in Therapeutics Development - Advancell - Aerpio Therapeutics, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Berg LLC - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Molecular Design International, Inc. - NatureWise Biotech & Medicals Corporation - Novan, Inc. - Omeros Corporation - Pacific Northwest Biotechnology, LLC - ProMetic Life Sciences Inc. - Regenics AS - RXi Pharmaceuticals Corporation - Sanofi - Symic Biomedical, Inc. - TGV-Laboratories For more information visit http://www.researchandmarkets.com/research/ww...s_pipeline
CRMD: 1.79 (unch), FGEN: 18.39 (-0.86), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13), OMER: 11.31 (-0.20)
Intellicell Biosciences' Flagship Partner, Regen Medical, PC Has Passed QAAAA Office Based Surgery Inspection
Marketwired - Tue Oct 13, 7:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that Regen Medical, PC, a New York regenerative medicine company, has passed The American Association for Accreditation of Ambulatory Surgery Facilities' inspection and is fully compliant.
IntelliCell BioSciences, Inc. Launches Sales Program for Its FDA Inspected Cellular Therapy Lab Suite
Marketwired - Tue Oct 06, 7:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that it has initiated an extensive sales and marketing program to offer its U.S. Food and Drug Administration (FDA) Inspected and Registered Cellular Lab Suite to Orthopedic and Pain Management facilities across the country. Over the last several months, IntelliCell has developed and trained an experienced and professional network of Independent Sales Representatives in New Jersey, Pennsylvania, Texas, Mississippi, Louisiana, Wisconsin and Minnesota. The Company anticipates enlisting additional sales representatives in several key markets within the next few months.
IntelliCell BioSciences Signs Letter of Intent With Prestigious Southeastern Medical Center for Cellular Therapy Lab Suite
Marketwired - Thu Oct 01, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today the Company has signed a Letter of Intent with a prestigious Medical Center (the Center) in the Southeastern U.S. for the purchase of an Intellicell U.S. Food and Drug Administration (FDA) registered Cellular Therapy Lab Suite.
IntelliCell Selects PCG Advisory for Public Relations
Marketwired - Tue Sep 29, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that it has engaged PCG Advisory Group (PCG) as their agency of record for strategic communications and public relations advisory services.
Ischemia - Pipeline Review, H1 2015
M2 - Thu Aug 20, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xd2ncc/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Alize Pharma - Amyndas Pharmaceuticals - AnGes - Apceth - Athersys - Bioheart - Caladrius Biosciences - Cellmid - CoDa Therapeutics - CohBar - DNAVEC Corporation - GlaxoSmithKline - Hemostemix - IntelliCell BioSciences - Juventas Therapeutics - Kasiak Research - Lixte Biotechnology - Mast Therapeutics - Mesoblast - Miltenyi Biotec - Mirrx Therapeutics - Multi Gene Vascular Systems - Nyken - Opsona Therapeutics - Pathfinder Cell Therapy - PharmaIN Corporation - Pharmicell - Pluristem Therapeutics - ReNeuron - Sihuan Pharmaceutical Holdings - Stempeutics Research - Taxus Cardium Pharmaceuticals Group - TikoMed - Vericel Corporation - ViroMed For more information visit http://www.researchandmarkets.com/research/xd2ncc/ischemia
VCEL: 2.13 (-0.03), MSTX: 0.42 (unch), PSTI: 1.66 (+0.07), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13)
Wounds - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Wounds
M2 - Mon Aug 17, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfxjz3/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H1 2015" report to their offering. Summary This, Wounds - Pipeline Review, H1 2015', provides an overview of the Wounds's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Advancell - Aerpio Therapeutics, Inc. - Agenta Biotechnologies, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - APEIRON Biologics AG - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - CYATHUS EXQUIRERE PharmaforschungsGmbH - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Garnet BioTherapeutics - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Kuros Biosurgery AG - LegoChem Biosciences, Inc - Living Cell Technologies Limited - MediWound Ltd. For more information visit http://www.researchandmarkets.com/research/wf...s_pipeline
CRMD: 1.79 (unch), MDWD: 6.37 (-0.37), FGEN: 18.39 (-0.86), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13)
Critical Limb Ischemia Therapeutics Pipeline Review, H1 2015 - 18 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc45jz/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bioheart, Inc. - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Multi Gene Vascular Systems Ltd - NeoStem, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group plc - Stempeutics Research Private Limited - TikoMed AB - Vericel Corporation - ViroMed Co., Ltd. Drug Profiles - ACP-01 - AdipoCell - Alecmestencel-T - AMR-001 - ASCT-01 - Autologous Vascular Cells Therapy - beperminogene perplasmid - Cell Therapy for Critical Limb Ischemia - Cellgram for Severe Lower Limb Ischemia - DVC1-0101 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - ixmyelocel-T - JVS-100 - MultiGeneAngio - MultiStem - PLX-PAD - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Protein for Critical Limb Ischemia - Refacell-CLI - ReN-009 - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Stempeucel - Stromal Cell Therapy for Critical Limb Ischemia - TM-700 - VM-202 For more information visit http://www.researchandmarkets.com/research/sc...tical_limb
VCEL: 2.13 (-0.03), PSTI: 1.66 (+0.07), NBS: 2.25 (-0.09), ATHX: 1.98 (-0.04)
IntelliCell BioSciences Licenses Indication for Diabetes to Invigorcell
PR Newswire - Tue Jan 27, 10:30AM CST
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, today announced a license agreement for the indication of Diabetes Mellitus.
IntelliCell BioSciences Announces Collaboration to Develop Closed Processing System for Cell Therapy Manufacturing
PR Newswire - Wed Jan 21, 12:21PM CST
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company" (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today an agreement for the development of a new closed processing system (the "System" for its cellular therapy manufacturing with Hielscher Ultrasonics. Under the agreement, Hielscher Ultrasonics will provide system design and engineering development for ultrasonic cavitation manufacturing, and IntelliCell Biosciences will use this system in its commercial application of its stromal vascular fraction cellular product, "SVFC."
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 5.70 (-0.66), CBMG: 13.74 (-0.31), OCAT: 8.47 (+0.01), ZBH: 128.30 (-1.61), PFE: 34.79 (-0.32), LLY: 79.84 (-0.42), GSK: 44.32 (-0.08), GLPG: 53.49 (-0.92), AXSM: 7.32 (+0.31), OMER: 11.31 (-0.20), CANF: 2.21 (-0.04), AST: 2.98 (-0.11), AKTX: 9.82 (+0.47)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.66 (+0.07), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13), MESO: 5.70 (-0.66), ATHX: 1.98 (-0.04), BXLT: 46.02 (-0.18)
Critical Limb Ischemia - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/htv6p6/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Critical Limb Ischemia Overview - Therapeutics Development - Pipeline Products for Critical Limb Ischemia - Overview - Pipeline Products for Critical Limb Ischemia - Comparative Analysis - Critical Limb Ischemia - Therapeutics under Development by Companies - Critical Limb Ischemia - Therapeutics under Investigation by Universities/Institutes - Critical Limb Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Critical Limb Ischemia - Products under Development by Companies - Critical Limb Ischemia - Products under Investigation by Universities/Institutes - Critical Limb Ischemia - Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Caladrius Biosciences, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Multi Gene Vascular Systems Ltd - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group Plc - Stempeutics Research Private Limited - Targazyme, Inc. - TikoMed AB - U.S. Stem Cell, Inc. - Vericel Corporation - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ht...tical_limb
VCEL: 2.13 (-0.03), PSTI: 1.66 (+0.07), ATHX: 1.98 (-0.04), CLBS: 5.88 (-0.13)
Global Wounds Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/wwsp8b/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wounds Overview - Therapeutics Development - Pipeline Products for Wounds - Overview - Pipeline Products for Wounds - Comparative Analysis - Wounds - Therapeutics under Development by Companies - Wounds - Therapeutics under Investigation by Universities/Institutes - Wounds - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wounds - Products under Development by Companies - Wounds - Products under Investigation by Universities/Institutes - Wounds - Companies Involved in Therapeutics Development - Advancell - Aerpio Therapeutics, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Berg LLC - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Molecular Design International, Inc. - NatureWise Biotech & Medicals Corporation - Novan, Inc. - Omeros Corporation - Pacific Northwest Biotechnology, LLC - ProMetic Life Sciences Inc. - Regenics AS - RXi Pharmaceuticals Corporation - Sanofi - Symic Biomedical, Inc. - TGV-Laboratories For more information visit http://www.researchandmarkets.com/research/ww...s_pipeline
CRMD: 1.79 (unch), FGEN: 18.39 (-0.86), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13), OMER: 11.31 (-0.20)
Intellicell Biosciences' Flagship Partner, Regen Medical, PC Has Passed QAAAA Office Based Surgery Inspection
Marketwired - Tue Oct 13, 7:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that Regen Medical, PC, a New York regenerative medicine company, has passed The American Association for Accreditation of Ambulatory Surgery Facilities' inspection and is fully compliant. IntelliCell BioSciences, Inc. Launches Sales Program for Its FDA Inspected Cellular Therapy Lab Suite
Marketwired - Tue Oct 06, 7:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that it has initiated an extensive sales and marketing program to offer its U.S. Food and Drug Administration (FDA) Inspected and Registered Cellular Lab Suite to Orthopedic and Pain Management facilities across the country. Over the last several months, IntelliCell has developed and trained an experienced and professional network of Independent Sales Representatives in New Jersey, Pennsylvania, Texas, Mississippi, Louisiana, Wisconsin and Minnesota. The Company anticipates enlisting additional sales representatives in several key markets within the next few months. IntelliCell BioSciences Signs Letter of Intent With Prestigious Southeastern Medical Center for Cellular Therapy Lab Suite
Marketwired - Thu Oct 01, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today the Company has signed a Letter of Intent with a prestigious Medical Center (the Center) in the Southeastern U.S. for the purchase of an Intellicell U.S. Food and Drug Administration (FDA) registered Cellular Therapy Lab Suite. IntelliCell Selects PCG Advisory for Public Relations
Marketwired - Tue Sep 29, 8:01AM CDT
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company pioneering a new proprietary medical process that results in acquiring Stromal Vascular Fraction Cells (SVFC), announced today that it has engaged PCG Advisory Group (PCG) as their agency of record for strategic communications and public relations advisory services. Ischemia - Pipeline Review, H1 2015
M2 - Thu Aug 20, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xd2ncc/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Alize Pharma - Amyndas Pharmaceuticals - AnGes - Apceth - Athersys - Bioheart - Caladrius Biosciences - Cellmid - CoDa Therapeutics - CohBar - DNAVEC Corporation - GlaxoSmithKline - Hemostemix - IntelliCell BioSciences - Juventas Therapeutics - Kasiak Research - Lixte Biotechnology - Mast Therapeutics - Mesoblast - Miltenyi Biotec - Mirrx Therapeutics - Multi Gene Vascular Systems - Nyken - Opsona Therapeutics - Pathfinder Cell Therapy - PharmaIN Corporation - Pharmicell - Pluristem Therapeutics - ReNeuron - Sihuan Pharmaceutical Holdings - Stempeutics Research - Taxus Cardium Pharmaceuticals Group - TikoMed - Vericel Corporation - ViroMed For more information visit http://www.researchandmarkets.com/research/xd2ncc/ischemia
VCEL: 2.13 (-0.03), MSTX: 0.42 (unch), PSTI: 1.66 (+0.07), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13)
Wounds - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Wounds
M2 - Mon Aug 17, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfxjz3/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H1 2015" report to their offering. Summary This, Wounds - Pipeline Review, H1 2015', provides an overview of the Wounds's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Advancell - Aerpio Therapeutics, Inc. - Agenta Biotechnologies, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - APEIRON Biologics AG - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - CYATHUS EXQUIRERE PharmaforschungsGmbH - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Garnet BioTherapeutics - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Kuros Biosurgery AG - LegoChem Biosciences, Inc - Living Cell Technologies Limited - MediWound Ltd. For more information visit http://www.researchandmarkets.com/research/wf...s_pipeline
CRMD: 1.79 (unch), MDWD: 6.37 (-0.37), FGEN: 18.39 (-0.86), GSK: 44.32 (-0.08), CLBS: 5.88 (-0.13)
Critical Limb Ischemia Therapeutics Pipeline Review, H1 2015 - 18 Companies & 28 Drug Profiles
M2 - Tue Jul 21, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sc45jz/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Bioheart, Inc. - DNAVEC Corporation - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Multi Gene Vascular Systems Ltd - NeoStem, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - ReNeuron Group plc - Stempeutics Research Private Limited - TikoMed AB - Vericel Corporation - ViroMed Co., Ltd. Drug Profiles - ACP-01 - AdipoCell - Alecmestencel-T - AMR-001 - ASCT-01 - Autologous Vascular Cells Therapy - beperminogene perplasmid - Cell Therapy for Critical Limb Ischemia - Cellgram for Severe Lower Limb Ischemia - DVC1-0101 - Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - ixmyelocel-T - JVS-100 - MultiGeneAngio - MultiStem - PLX-PAD - Protein for Myocardial Infarction and Critical Limb Ischemia - Recombinant Protein for Critical Limb Ischemia - Refacell-CLI - ReN-009 - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy for Critical Limb Ischemia - Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia - Stempeucel - Stromal Cell Therapy for Critical Limb Ischemia - TM-700 - VM-202 For more information visit http://www.researchandmarkets.com/research/sc...tical_limb
VCEL: 2.13 (-0.03), PSTI: 1.66 (+0.07), NBS: 2.25 (-0.09), ATHX: 1.98 (-0.04)
IntelliCell BioSciences Licenses Indication for Diabetes to Invigorcell
PR Newswire - Tue Jan 27, 10:30AM CST
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, today announced a license agreement for the indication of Diabetes Mellitus. IntelliCell BioSciences Announces Collaboration to Develop Closed Processing System for Cell Therapy Manufacturing
PR Newswire - Wed Jan 21, 12:21PM CST
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company"
(OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels found in adipose tissue, announced today an agreement for the development of a new closed processing system (the "System" for its cellular therapy manufacturing with Hielscher Ultrasonics. Under the agreement, Hielscher Ultrasonics will provide system design and engineering development for ultrasonic cavitation manufacturing, and IntelliCell Biosciences will use this system in its commercial application of its stromal vascular fraction cellular product, "SVFC." 
